Knowthestock.com
CSBR - Champions Oncology Inc

Sell

Weak GrowthStock Price Very High
WeakStrong
WeakStrong

33%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 19.03%
Operating Income turning Positive
Net Income turning Positive
Earnings Per Share (EPS) turning Positive
Net Margin is 10.93%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 0.99
Debt Ratio is 0.82
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Champions Oncology Inc (CSBR) - https://championsoncology.com
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO -
Employees - 198
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.